Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 single-arm open-label study of nirogacestat in premenopausal adult females with desmoid tumors
2024-515215-21-00Phase 4Authorised
- Sponsor
- SpringWorks Therapeutics
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, open-label, single-arm trial of nirogacestat in aggressive fibromatosis (AF), sponsored by SpringWorks Therapeutics. Primary endpoint: Ovarian function recovery rate of ovarian toxicity TEAEs. Planned start Sep 2025; status: authorised.
02
Drugs
nirogacestat
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on 2024-515215-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515215-21-00.